Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-26 @ 3:17 PM
NCT ID:
NCT07380269
Eligibility Criteria:
Inclusion Criteria:
* Patients with severe or greater hearing loss (≥65 dB) scheduled to receive cochlear implant (CI) treatment.
* No restrictions on age or gender.
* Native language is Mandarin Chinese.
* The subject and/or their legal guardian must provide informed consent prior to the study, voluntarily sign a written informed consent form, and be willing to undergo follow-up assessments at the specified time points.
* Ability to communicate effectively with the researcher with the help of a guardian and comply with the researcher's requirements. For young children without mature language skills, ability to cooperate with the help of a guardian.
* The subject's guardian has a correct understanding of the trial and realistic expectations of potential benefits.
Exclusion Criteria:
* Presence of other severe diseases unsuitable for cochlear implantation surgery.
* Significant psychological problems or mood disorders (e.g., notable anxiety, depression, or behavioral disorders) that would preclude cooperation with training and follow-up.
* Neurological diseases (e.g., epilepsy, cerebral palsy) that may affect auditory processing ability.
* Concurrent participation in other interventional studies involving drugs or behavioral interventions that may affect auditory rehabilitation during the study period.
* Any other condition considered by the investigator to make the subject unsuitable for participation in this clinical study.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT07380269
Study Brief:
Protocol Section:
NCT07380269